Ironwood Total Stockholder Equity vs Other Current Assets Analysis

IRWD Stock

USD 7.82 0.26 3.22%

Ironwood Pharmaceuticals financial indicator trend analysis is infinitely more than just investigating Ironwood Pharmaceuticals recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Ironwood Pharmaceuticals is a good investment. Please check the relationship between Ironwood Pharmaceuticals Total Stockholder Equity and its Other Current Assets accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ironwood Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in housing.

For information on how to trade Ironwood Stock refer to our How to Trade Ironwood Stock guide.

Total Stockholder Equity vs Other Current Assets

Total Stockholder Equity vs Other Current Assets Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Ironwood Pharmaceuticals Total Stockholder Equity account and Other Current Assets. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between Ironwood Pharmaceuticals' Total Stockholder Equity and Other Current Assets is -0.3. Overlapping area represents the amount of variation of Total Stockholder Equity that can explain the historical movement of Other Current Assets in the same time period over historical financial statements of Ironwood Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Ironwood Pharmaceuticals' Total Stockholder Equity and Other Current Assets is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Stockholder Equity of Ironwood Pharmaceuticals are associated (or correlated) with its Other Current Assets. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Other Current Assets has no effect on the direction of Total Stockholder Equity i.e., Ironwood Pharmaceuticals' Total Stockholder Equity and Other Current Assets go up and down completely randomly.

Correlation Coefficient

-0.3

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Total Stockholder Equity

The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.

Other Current Assets

Assets expected to be converted into cash, sold, or consumed either in one year or in the operating cycle, which are not included under standard current asset categories.

Most indicators from Ironwood Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Ironwood Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ironwood Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in housing.

For information on how to trade Ironwood Stock refer to our How to Trade Ironwood Stock guide.At present, Ironwood Pharmaceuticals' Sales General And Administrative To Revenue is projected to slightly decrease based on the last few years of reporting. The current year's Enterprise Value Over EBITDA is expected to grow to 11.97, whereas Selling General Administrative is forecasted to decline to about 138.7 M.

	2021	2022	2023	2024 (projected)
Interest Expense	31.2M	7.6M	21.6M	19.9M
Depreciation And Amortization	682K	9.5M	1.6M	1.5M

Interest Expense Depreciation And Amortization

Ironwood Pharmaceuticals fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets
Total Assets		0.51	-0.01	0.13	0.7	0.05	-0.19	0.16	-0.16	-0.18	-0.2	0.83	0.87	0.26	0.93	0.6	0.87	0.6	0.56	0.78	0.52	0.21	0.66	0.49	-0.2	0.95
Short Long Term Debt Total	0.51		0.61	0.72	-0.21	-0.11	-0.31	-0.26	0.7	-0.85	-0.17	0.25	0.53	0.14	0.23	0.83	0.14	0.91	0.67	0.73	0.76	0.78	0.74	0.82	-0.2	0.44
Other Current Liab	-0.01	0.61		0.75	-0.46	-0.28	-0.13	-0.28	0.68	-0.43	-0.43	-0.19	0.13	-0.29	-0.25	0.22	-0.35	0.5	0.15	0.14	0.23	0.55	0.08	0.34	0.03	-0.1
Total Current Liabilities	0.13	0.72	0.75		-0.42	-0.21	-0.24	-0.12	0.72	-0.55	-0.13	-0.12	0.3	-0.21	-0.09	0.29	-0.25	0.52	0.29	0.2	0.27	0.68	0.24	0.48	-0.08	0.01
Total Stockholder Equity	0.7	-0.21	-0.46	-0.42		-0.09	0.24	0.41	-0.78	0.44	-0.18	0.81	0.47	0.01	0.82	0.01	0.9	-0.04	0.19	0.36	-0.15	-0.3	0.22	-0.2	0.14	0.75
Other Liab	0.05	-0.11	-0.28	-0.21	-0.09		-0.29	-0.19	0.15	-0.01	0.66	-0.33	0.3	0.89	0.06	0.11	-0.03	-0.19	-0.05	-0.08	0.38	-0.26	-0.01	0.29	-0.34	-0.12
Property Plant And Equipment Net	-0.19	-0.31	-0.13	-0.24	0.24	-0.29		0.11	-0.23	0.12	0.03	-0.06	-0.29	-0.21	-0.18	-0.27	0.0	-0.39	0.25	-0.06	-0.58	0.01	0.04	-0.56	0.97	-0.1
Current Deferred Revenue	0.16	-0.26	-0.28	-0.12	0.41	-0.19	0.11		-0.48	0.36	-0.46	0.33	0.02	-0.2	0.28	-0.25	0.32	-0.11	-0.15	-0.16	-0.3	-0.39	-0.11	-0.25	0.06	0.22
Net Debt	-0.16	0.7	0.68	0.72	-0.78	0.15	-0.23	-0.48		-0.79	0.16	-0.52	0.08	0.19	-0.43	0.45	-0.55	0.46	0.32	0.17	0.52	0.68	0.29	0.6	-0.09	-0.29
Retained Earnings	-0.18	-0.85	-0.43	-0.55	0.44	-0.01	0.12	0.36	-0.79		-0.13	0.05	-0.23	-0.3	0.07	-0.8	0.13	-0.74	-0.73	-0.64	-0.7	-0.81	-0.77	-0.74	0.03	-0.12
Accounts Payable	-0.2	-0.17	-0.43	-0.13	-0.18	0.66	0.03	-0.46	0.16	-0.13		-0.41	0.0	0.58	-0.15	0.01	-0.2	-0.35	0.12	-0.06	0.07	0.03	0.06	0.06	-0.02	-0.3
Cash	0.83	0.25	-0.19	-0.12	0.81	-0.33	-0.06	0.33	-0.52	0.05	-0.41		0.52	-0.09	0.86	0.38	0.91	0.46	0.37	0.64	0.21	0.02	0.49	0.17	-0.11	0.92
Non Current Assets Total	0.87	0.53	0.13	0.3	0.47	0.3	-0.29	0.02	0.08	-0.23	0.0	0.52		0.4	0.79	0.59	0.59	0.54	0.51	0.65	0.59	0.2	0.56	0.63	-0.24	0.67
Non Currrent Assets Other	0.26	0.14	-0.29	-0.21	0.01	0.89	-0.21	-0.2	0.19	-0.3	0.58	-0.09	0.4		0.24	0.44	0.17	0.09	0.29	0.27	0.6	-0.05	0.37	0.48	-0.28	0.14
Other Assets	0.93	0.23	-0.25	-0.09	0.82	0.06	-0.18	0.28	-0.43	0.07	-0.15	0.86	0.79	0.24		0.4	0.9	0.39	0.36	0.62	0.33	-0.02	0.49	0.3	-0.23	0.88
Long Term Debt	0.6	0.83	0.22	0.29	0.01	0.11	-0.27	-0.25	0.45	-0.8	0.01	0.38	0.59	0.44	0.4		0.36	0.82	0.81	0.89	0.9	0.51	0.9	0.89	-0.17	0.53
Cash And Short Term Investments	0.87	0.14	-0.35	-0.25	0.9	-0.03	0.0	0.32	-0.55	0.13	-0.2	0.91	0.59	0.17	0.9	0.36		0.27	0.39	0.62	0.22	-0.11	0.48	0.16	-0.07	0.94
Net Receivables	0.6	0.91	0.5	0.52	-0.04	-0.19	-0.39	-0.11	0.46	-0.74	-0.35	0.46	0.54	0.09	0.39	0.82	0.27		0.6	0.78	0.76	0.67	0.74	0.77	-0.31	0.56
Common Stock Total Equity	0.56	0.67	0.15	0.29	0.19	-0.05	0.25	-0.15	0.32	-0.73	0.12	0.37	0.51	0.29	0.36	0.81	0.39	0.6		0.88	0.52	0.59	0.95	0.58	0.33	0.51
Common Stock Shares Outstanding	0.78	0.73	0.14	0.2	0.36	-0.08	-0.06	-0.16	0.17	-0.64	-0.06	0.64	0.65	0.27	0.62	0.89	0.62	0.78	0.88		0.68	0.55	0.94	0.66	-0.02	0.77
Non Current Liabilities Total	0.52	0.76	0.23	0.27	-0.15	0.38	-0.58	-0.3	0.52	-0.7	0.07	0.21	0.59	0.6	0.33	0.9	0.22	0.76	0.52	0.68		0.37	0.68	0.95	-0.51	0.4
Other Current Assets	0.21	0.78	0.55	0.68	-0.3	-0.26	0.01	-0.39	0.68	-0.81	0.03	0.02	0.2	-0.05	-0.02	0.51	-0.11	0.67	0.59	0.55	0.37		0.6	0.44	0.08	0.18
Other Stockholder Equity	0.66	0.74	0.08	0.24	0.22	-0.01	0.04	-0.11	0.29	-0.77	0.06	0.49	0.56	0.37	0.49	0.9	0.48	0.74	0.95	0.94	0.68	0.6		0.68	0.08	0.63
Total Liab	0.49	0.82	0.34	0.48	-0.2	0.29	-0.56	-0.25	0.6	-0.74	0.06	0.17	0.63	0.48	0.3	0.89	0.16	0.77	0.58	0.66	0.95	0.44	0.68		-0.43	0.34
Property Plant And Equipment Gross	-0.2	-0.2	0.03	-0.08	0.14	-0.34	0.97	0.06	-0.09	0.03	-0.02	-0.11	-0.24	-0.28	-0.23	-0.17	-0.07	-0.31	0.33	-0.02	-0.51	0.08	0.08	-0.43		-0.15
Total Current Assets	0.95	0.44	-0.1	0.01	0.75	-0.12	-0.1	0.22	-0.29	-0.12	-0.3	0.92	0.67	0.14	0.88	0.53	0.94	0.56	0.51	0.77	0.4	0.18	0.63	0.34	-0.15

Click cells to compare fundamentals

Ironwood Pharmaceuticals Account Relationship Matchups

Ironwood Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	402.7M	559.2M	1.1B	1.1B	471.1M	499.5M
Short Long Term Debt Total	431.2M	453.7M	475.8M	415.9M	715.5M	751.3M
Other Current Liab	33.4M	540K	1.3M	22.0M	64.3M	67.6M
Total Current Liabilities	40.9M	32.7M	161.7M	25.5M	276.1M	289.9M
Total Stockholder Equity	(93.3M)	62.6M	605.9M	652.4M	(346.3M)	(329.0M)
Other Liab	25.0M	13.3M	3.5M	9.8M	8.8M	8.3M
Property Plant And Equipment Net	30.2M	25.5M	22.9M	20.3M	18.2M	19.6M
Current Deferred Revenue	875K	28.4M	39.5M	1.2M	1.1M	1.1M
Net Debt	254.2M	91.1M	(144.3M)	(240.3M)	623.4M	654.6M
Retained Earnings	(1.6B)	(1.5B)	(937.6M)	(696.4M)	(1.7B)	(1.6B)
Accounts Payable	5.5M	661K	935K	483K	7.8M	7.4M
Cash	177.0M	362.6M	620.1M	656.2M	92.2M	87.5M
Non Current Assets Total	95.9M	63.4M	381.7M	319.9M	237.8M	143.0M
Non Currrent Assets Other	64.9M	37.1M	25.5M	15.9M	3.6M	3.4M
Other Assets	64.9M	54.5M	358.8M	299.6M	1.0	0.95
Long Term Debt	408.0M	430.3M	337.3M	396.3M	498.3M	252.1M
Cash And Short Term Investments	177.0M	362.6M	620.1M	656.2M	92.2M	87.5M
Net Receivables	117.2M	122.4M	114.0M	115.5M	129.1M	135.6M
Common Stock Total Equity	154K	158K	161K	162K	177.1K	125.3K
Common Stock Shares Outstanding	156.0M	160.7M	164.4M	186.3M	155.4M	137.1M
Liabilities And Stockholders Equity	402.7M	559.2M	1.1B	1.1B	471.1M	499.5M
Non Current Liabilities Total	455.1M	463.9M	359.3M	422.6M	541.3M	370.6M
Other Current Assets	11.9M	9.2M	9.8M	7.7M	12.0M	17.6M
Other Stockholder Equity	1.5B	1.5B	1.5B	1.3B	1.4B	1.0B
Total Liab	496.0M	496.6M	521.0M	448.1M	817.4M	454.8M
Property Plant And Equipment Gross	30.2M	25.5M	22.9M	20.3M	27.1M	20.1M
Total Current Assets	306.9M	495.8M	745.2M	780.6M	233.3M	356.5M
Accumulated Other Comprehensive Income	(79K)	(65.2M)	0.0	(11.8M)	(3.0M)	(3.2M)
Short Term Debt	1.1M	3.1M	120.0M	3.1M	202.7M	212.8M
Common Stock	154K	158K	161K	162K	156K	128.1K
Property Plant Equipment	12.4M	8.9M	22.9M	6.3M	5.7M	5.4M
Net Tangible Assets	(72.0M)	83.0M	605.9M	669.0M	769.3M	807.8M
Retained Earnings Total Equity	(1.6B)	(1.5B)	(937.6M)	(696.4M)	(626.7M)	(658.1M)
Long Term Debt Total	408.0M	430.3M	337.3M	396.3M	455.7M	311.5M
Capital Surpluse	1.5B	1.5B	1.5B	1.3B	1.6B	1.3B
Capital Lease Obligations	23.2M	23.4M	21.6M	19.7M	17.7M	9.9M
Deferred Long Term Liab	97.6M	40.1M	24.3M	12.1M	13.9M	13.2M

Ironwood Pharmaceuticals Investors Sentiment

The influence of Ironwood Pharmaceuticals' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Ironwood. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.

Investor biases related to Ironwood Pharmaceuticals' public news can be used to forecast risks associated with an investment in Ironwood. The trend in average sentiment can be used to explain how an investor holding Ironwood can time the market purely based on public headlines and social activities around Ironwood Pharmaceuticals. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.

Ironwood Pharmaceuticals' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Ironwood Pharmaceuticals' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Ironwood Pharmaceuticals' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Ironwood Pharmaceuticals.

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Ironwood Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Ironwood Pharmaceuticals' short interest history, or implied volatility extrapolated from Ironwood Pharmaceuticals options trading.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Ironwood Pharmaceuticals is a strong investment it is important to analyze Ironwood Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ironwood Pharmaceuticals' future performance. For an informed investment choice regarding Ironwood Stock, refer to the following important reports:

How To Invest In Ironwood

Details

Is Ironwood Stock a good investment?

Details

What is Ironwood Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ironwood Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in housing.

For information on how to trade Ironwood Stock refer to our How to Trade Ironwood Stock guide.

You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.

Complementary Tools for Ironwood Stock analysis

When running Ironwood Pharmaceuticals' price analysis, check to measure Ironwood Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ironwood Pharmaceuticals is operating at the current time. Most of Ironwood Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Ironwood Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ironwood Pharmaceuticals' price. Additionally, you may evaluate how the addition of Ironwood Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

	Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
	Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings
	Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
	Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges
	Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
	Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
	Analyst Advice Analyst recommendations and target price estimates broken down by several categories
	My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
	Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios

Is Ironwood Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ironwood Pharmaceuticals. If investors know Ironwood will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ironwood Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.69)

Earnings Share

(6.45)

Revenue Per Share

2.848

Quarterly Revenue Growth

0.097

Return On Assets

0.1339

The market value of Ironwood Pharmaceuticals is measured differently than its book value, which is the value of Ironwood that is recorded on the company's balance sheet. Investors also form their own opinion of Ironwood Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Ironwood Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ironwood Pharmaceuticals' market value can be influenced by many factors that don't directly affect Ironwood Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Ironwood Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ironwood Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ironwood Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Ironwood Total Stockholder Equity vs Other Current Assets Analysis

Total Stockholder Equity vs Other Current Assets

Total Stockholder Equity vs Other Current Assets Correlation Analysis

Correlation Coefficient

Total Stockholder Equity

Other Current Assets

Ironwood Pharmaceuticals fundamental ratios Correlations

Ironwood Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Ironwood Pharmaceuticals fundamental ratios Accounts

Ironwood Pharmaceuticals Investors Sentiment

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for Ironwood Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Property Plant And Equipment Gross	+ 0.97	Property Plant And Equipment Net
Total Current Assets	+ 0.95	Total Assets
Other Stockholder Equity	+ 0.95	Common Stock Total Equity
Total Liab	+ 0.95	Non Current Liabilities Total
Total Current Assets	+ 0.94	Cash And Short Term Investments
Other Stockholder Equity	+ 0.94	Common Stock Shares Outstanding

Retained Earnings	- 0.85	Short Long Term Debt Total
Other Current Assets	- 0.81	Retained Earnings
Long Term Debt	- 0.8	Retained Earnings
Retained Earnings	- 0.79	Net Debt
Net Debt	- 0.78	Total Stockholder Equity
Other Stockholder Equity	- 0.77	Retained Earnings